Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias
AssigneesEspoirXLHED Sàrl, Friedrich-Alexander-Universitaet Erlangen-Nuernberg
InventorsPascal Schneider, Kenneth M. Huttner, Neil Kirby, Holm Schneider
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.
Claims10
A method for altering one or more phenotypic presentations of ectodermal dysplasia in a mammalian organism diagnosed with or suspected of having ectodermal dysplasia comprising, administering to said mammalian organism a pharmaceutical composition comprising EDI200, wherein administration is via an intra-amniotic route and wherein the pharmaceutical composition is administered in a dose of between 1 mg/kg and 100 mg/kg of fetal weight.
A method for treating hypohidrotic ectodermal dysplasia in a mammalian organism diagnosed with or suspected of having hypohidrotic ectodermal dysplasia comprising, administering to said mammalian organism an effective amount of a pharmaceutical composition comprising EDI200, wherein administration is via an intra-amniotic route and wherein the pharmaceutical composition is administered in a dose of between 1 mg/kg and 100 mg/kg of fetal weight.
Dependencies are inferred from the claim text.